Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | CA2 | P00918 | 4/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.50 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1797197 | 0.83 | MAPT (0.59) | MAPTGAACA1CA2CA12 | |
| SCHEMBL8702369 | 0.83 | MAPT (0.59) | MAPTGAACA1CA2CA12 | |
| Hydrochloric Acid SCHEMBL3655605 | 0.83 | MAPT (0.59) | MAPTGAACA1CA2CA12 | |
| SCHEMBL9779998 | 0.83 | MAPT (0.59) | MAPTGAACA1CA2CA12 | |
| SCHEMBL9645505 | 0.82 | CA1 (0.54) | MAPTGAACA1CA2CA12 | |
| SCHEMBL6905909 | 0.82 | MAPT (0.53) | MAPTGAACA1CA2CA12 | |
| SCHEMBL5438871 | 0.82 | CA1 (0.56) | MAPTGAACA1CA2CA12 | |
| Hydrochloric Acid SCHEMBL9527013 | 0.81 | MAPT (0.57) | MAPTGAACA1CA2CA12 | |
| Hydrochloric Acid SCHEMBL5122021 | 0.81 | MAPT (0.57) | MAPTGAACA1CA2CA12 | |
| SCHEMBL1180270 | 0.80 | CA1 (0.76) | MAPTGAACA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | claimed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | claimed |
| EP-1971600-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK Holdings Co., Ltd. (KR) | 2008-09-24 | — | — | EP | claimed |
| US-20080207683-A1 | BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | claimed |
| WO-2008100622-A2 | BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| WO-2007078113-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2007-07-12 | — | — | WO | claimed |
| CN-115353667-A | Method and material for reducing waste | 李蓁蓁 | 2022-11-18 | — | — | CN | disclosed |
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | disclosed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | disclosed |
| EP-1971600-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK Holdings Co., Ltd. (KR) | 2008-09-24 | — | — | EP | disclosed |
| US-20080207683-A1 | BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
| WO-2008100622-A2 | BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| EP-1910286-A2 | CATHEPSIN K INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| EP-0030848-B1 | PHARMACOLOGICALLY ACTIVE PEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ELI LILLY AND COMPANY (US) | 1985-02-13 | — | — | EP | disclosed |
| EP-0030846-B1 | PHARMACOLOGICALLY ACTIVE PEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ELI LILLY AND COMPANY (US) | 1984-05-09 | — | — | EP | disclosed |
| US-4351763-A | Pharmacologically active peptides | ELI LILLY AND COMPANY (US) | 1982-09-28 | — | — | US | disclosed |
| US-4283329-A | ANALGESICS | ELI LILLY AND COMPANY (US) | 1981-08-11 | — | — | US | disclosed |
| EP-0030848-A2 | Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them | ELI LILLY AND COMPANY (US) | 1981-06-24 | — | — | EP | disclosed |
| EP-0030846-A2 | Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them | ELI LILLY AND COMPANY (US) | 1981-06-24 | — | — | EP | disclosed |
| US-4251439-A | ENKEPHALIN ANALOGS AS ANALGESICS | ELI LILLY AND COMPANY (US) | 1981-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | MAPT 2497/4885GAA 1611/4885CA1 4150/4885 |
| US-20080207683-A1 | BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | MAPT 1422/4885GAA 143/4885CA1 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.